Tremfya (guselkumab) - J&J
Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) - GSK, Innoviva, Theravance Biopharma
Promacta (eltrombopag) - Novartis
Voranigo (vorasidenib) - Servier
https://www.manilatimes.net/2026/02/11/tmt-newswire/globenewswire/royalty-pharma-reports-q4-and-full-year-2025-results/2276117
 
Feb 11, 2026
 
Next